ArticleAntibiotics (Basel, Switzerland)2021
Novel Cecropin-4 Derived Peptides against Methicillin-Resistant
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- CAMPER: mechanistic artificial intelligence for designing peptides that target MRSA persisters.Nature communications · 2026Article
- The Evolution of Symbiosis inBiomolecules · 2026Review
- Novel antibacterial peptide HfAMP against methicillin-resistant Staphylococcus aureus.BMC microbiology · 2025Article
- Development of novel broad-spectrum amphipathic antimicrobial peptides against multidrug-resistant bacteria through a rational combination strategy.Journal of advanced research · 2025Article
- The antimicrobial peptide Cec4 has therapeutic potential against clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Characterization of the antagonistic secondary metabolites ofFrontiers in microbiology · 2025Article
- Synergistic use of anti-inflammatory ketorolac and gentamicin to target staphylococcal biofilms.Journal of translational medicine · 2024Article
- Cecropin AD reduces viral load and inflammatory response against H9N2 avian influenza virus in chickens.Frontiers in veterinary science · 2024Article
- Synergistic use of anti-inflammatory ketorolac and gentamicin to target staphylococcal biofilms.Research square · 2023Article
- The Combination of Antibiotic and Non-Antibiotic Compounds Improves Antibiotic Efficacy against Multidrug-Resistant Bacteria.International journal of molecular sciences · 2023Review
- Antimicrobial Peptides and Small Molecules Targeting the Cell Membrane of Staphylococcus aureus.Microbiology and molecular biology reviews : MMBR · 2023Review
- Synergistic Antibiotic Activity of Ricini Semen Extract with Oxacillin against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Protective role of Cecropin AD against LPS-induced intestinal mucosal injury in chickens.Frontiers in immunology · 2023Article
- Cec4-Derived Peptide Inhibits Planktonic and Biofilm-Associated Methicillin Resistant Staphylococcus epidermidis.Microbiology spectrum · 2022Article
- Silver Carboxylate as an Antibiotic-Independent Antimicrobial: A Review of Current Formulations,Medical research archives · 2022Article
- Design and Evaluation of Short Bovine Lactoferrin-Derived Antimicrobial Peptides against Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Article
- A Cecropin-4 Derived Peptide C18 InhibitsFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Increasing microbial resistance, coupled with a lack of new antimicrobial discovery, has led researchers to refocus on antimicrobial peptides (AMPs) as novel therapeutic candidates. Significantly, the less toxic cecropins have gained widespread attention for potential antibacterial agent development. However, the narrow activity spectrum and long sequence remain the primary limitations of this approach. In this study, we truncated and modified cecropin 4 (41 amino acids) by varying the charge and hydrophobicity balance to obtain smaller AMPs. The derivative peptide C18 (16 amino acids) demonstrated high antibacterial activity against Gram-negative and Gram-positive bacteria, as well as yeasts. Moreover, C18 demonstrated a minimal inhibitory concentration (MIC) of 4 µg/mL against the methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.